A multi-architecture study of specificity refinement and false-positive mechanism analysis in prostate MRI
Why prostate cancer screening AI mistakes benign tissue for tumors
Machine learning models designed to detect prostate cancer via MRI consistently misidentify benign tissue as cancerous — not because the AI is flawed, but because the benign tissue genuinely looks like cancer on the imaging scans themselves. Across five different neural network architectures, false positives shared the same contrast patterns (brightness and darkness signatures) as actual tumors, suggesting this is a fundamental property of how prostate tissue appears on MRI rather than a quirk of any single AI system. Adding a small refinement layer improved accuracy in one test set but showed unpredictable results in others, indicating the fix doesn't reliably transfer.
Prostate cancer screening using AI MRI analysis can reduce unnecessary biopsies, but only if the algorithm reliably distinguishes real tumors from look-alike tissue. This work reveals the root cause of false positives — benign regions that genuinely mimic cancer's imaging signature — which means improving accuracy may require better imaging protocols or different detection strategies, not just better algorithms. The inconsistent performance of the refinement approach across test sets also warns clinicians that published accuracy numbers may not hold up in their own patient populations.